Download PDF
CC BY 4.0 · Journal of Clinical Interventional Radiology ISVIR 2024; 08(02): 079-082
DOI: 10.1055/s-0044-1778703
Original Article

Transjugular Intrahepatic Portosystemic Shunt Reduction for Medically Refractory Hepatic Encephalopathy

Brandon Toliver 
1   Department of Radiology & Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana
,
Matthew Thornburg 
1   Department of Radiology & Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana
,
Adam Schmitz 
1   Department of Radiology & Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana
,
Paul Haste
1   Department of Radiology & Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Purpose Transjugular intrahepatic portosystemic shunt (TIPS) is an established intervention for symptomatic portal hypertension, with many patients experiencing hepatic encephalopathy (HE) as an undesirable side effect. For medically refractory HE, TIPS reduction can decrease the burden of neurotoxic metabolites. This study aimed to evaluate the efficacy of TIPS reduction for the treatment of medically refractory post-TIPS HE.

Methods A retrospective search using an institutional database yielded 45 patients who underwent TIPS reduction between 2011 and 2021. Four patients were excluded due to lack of post-TIPS HE, and 41 patients in total were included. The primary endpoint was improvement of HE after TIPS reduction as measured by the West Haven scores. Secondary endpoints included postreduction recurrence of ascites or gastrointestinal bleeding, procedural complications, and 30-day mortality.

Results TIPS reduction was performed in all 41 patients with a 30-day mortality rate of 9.8%. No deaths were attributable to the procedure itself. Twenty-seven patients (65.9%) had improvement in HE and 10 patients (24.4%) proceeded to TIPS occlusion due to refractory HE. The average pre- and postreduction West Haven grades were 2.9 ± 0.5 and 1.9 ± 1.2 (p < 0.001), respectively. One patient (2.4%) had spontaneous TIPS thrombosis after reduction and developed arterial gastrointestinal bleeding, 15 patients (36.6%) experienced recurrent ascites, and there were no cases of variceal hemorrhage.

Conclusion In this population, TIPS reduction improved medically refractory HE in 65.9% of patients with a 36.6% risk of recurrent ascites, no cases of variceal hemorrhage, and 9.8% 30-day mortality.

Keywords

transjugular intrahepatic portosystemic shunt - Hepatic encephalopathy - TIPS reduction

Ethical approval

This retrospective study was conducted at a single university medical center, was approved by the institutional review board, and was HIPAA compliant.




Publication History

Article published online:
08 February 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Copelan A, Kapoor B, Sands M. Transjugular intrahepatic portosystemic shunt: indications, contraindications, and patient work-up. Semin Intervent Radiol 2014; 31 (03) 235-242
    Thieme ConnectPubMedSearch in Google Scholar
  • 2 Fares N, Robic MA, Péron JM. et al. Transjugular intrahepatic portosystemic shunt placement before abdominal intervention in cirrhotic patients with portal hypertension: lessons from a pilot study. Eur J Gastroenterol Hepatol 2018; 30 (01) 21-26
    CrossrefPubMedSearch in Google Scholar
  • 3 Riggio O, Nardelli S, Moscucci F, Pasquale C, Ridola L, Merli M. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Clin Liver Dis 2012; 16 (01) 133-146
    CrossrefPubMedSearch in Google Scholar
  • 4 Weissenborn K. Hepatic encephalopathy: definition, clinical grading and diagnostic principles. Drugs 2019; 79 (Suppl. 01) 5-9
    CrossrefPubMedSearch in Google Scholar
  • 5 Hudson M, Schuchmann M. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. Eur J Gastroenterol Hepatol 2019; 31 (04) 434-450
    CrossrefPubMedSearch in Google Scholar
  • 6 Nardelli S, Gioia S, Ridola L, Riggio O. Radiological intervention for shunt related encephalopathy. J Clin Exp Hepatol 2018; 8 (04) 452-459
    CrossrefPubMedSearch in Google Scholar
  • 7 Pereira K, Carrion AF, Salsamendi J, Doshi M, Baker R, Kably I. Endovascular management of refractory hepatic encephalopathy complication of transjugular intrahepatic portosystemic shunt (TIPS): comprehensive review and clinical practice algorithm. Cardiovasc Intervent Radiol 2016; 39 (02) 170-182
    CrossrefPubMedSearch in Google Scholar
  • 8 Taylor AG, Kolli KP, Kerlan Jr RK. Techniques for transjugular intrahepatic portosystemic shunt reduction and occlusion. Tech Vasc Interv Radiol 2016; 19 (01) 74-81
    CrossrefPubMedSearch in Google Scholar
  • 9 Schindler P, Seifert L, Masthoff M. et al. TIPS Modification in the management of shunt-induced hepatic encephalopathy: analysis of predictive factors and outcome with shunt modification. J Clin Med 2020; 9 (02) 567
    CrossrefPubMedSearch in Google Scholar
  • 10 Sarwar A, Esparaz AM, Chakrala N. et al. Efficacy of TIPS reduction for refractory hepatic encephalopathy, right heart failure, and liver dysfunction. AJR Am J Roentgenol 2021; 216 (05) 1267-1272
    CrossrefPubMedSearch in Google Scholar
  • 11 Kochar N, Tripathi D, Ireland H, Redhead DN, Hayes PC. Transjugular intrahepatic portosystemic stent shunt (TIPSS) modification in the management of post-TIPSS refractory hepatic encephalopathy. Gut 2006; 55 (11) 1617-1623
    CrossrefPubMedSearch in Google Scholar